The human metapneumovirus diagnostics market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historical period can be attributed to an increase in pediatric hospitalization rates due to respiratory infections, heightened awareness of viral respiratory pathogens, the initial adoption of molecular diagnostic tools, the expansion of public health surveillance programs, and greater funding for pediatric respiratory diseases.
The human metapneumovirus diagnostics market size is expected to see rapid growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth anticipated in the forecast period is driven by rising demand for early and accurate respiratory infection diagnostics, growing investments in point-of-care diagnostic solutions, expanding healthcare access in emerging markets, a global focus on pandemic preparedness, and greater integration of multiplex respiratory panels. Key trends in the forecast period include the development of automated and high-throughput diagnostic systems, a shift toward decentralized diagnostic models, the use of artificial intelligence in diagnostic interpretation, the increasing adoption of at-home testing kits, and growing collaboration between public and private diagnostic companies.
The increasing prevalence of respiratory infections is expected to drive growth in the human metapneumovirus diagnostics market. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the respiratory system, including the sinuses, throat, airways, and lungs. The rising prevalence can be linked to the exposure to harmful pollutants that irritate and weaken the respiratory tract, making it more susceptible to infections. Human metapneumovirus diagnostics help identify hMPV as the cause of respiratory infections, allowing for accurate treatment and better management. For example, in January 2025, the UK Health Security Agency reported that during the 2023-2024 season, respiratory infection rates in England peaked at 8 per 100,000 in weeks 50 and 52 of 2023, and rose further to 10.2 per 100,000 in week 4 of 2024, while acute respiratory infection incidents in closed settings reached 2,051, with most cases reported in care homes and hospitals. This growing prevalence of respiratory infections is fueling the expansion of the human metapneumovirus diagnostics market.
Leading companies in the human metapneumovirus diagnostics market are focusing on developing innovative solutions, such as respiratory polymerase chain reaction (PCR) diagnostic tools, to enhance molecular diagnostic capabilities for detecting a wide range of respiratory pathogens. A respiratory PCR diagnostic solution is a molecular testing method used to detect and identify respiratory pathogens by amplifying their genetic material with high sensitivity and specificity. For example, in March 2023, Jiangsu BioPerfectus Technologies Co., Ltd., a molecular diagnostic company based in China, launched its respiratory pathogen multiplex real-time PCR diagnostic kit. This solution is designed to simultaneously detect multiple respiratory pathogens with high accuracy and a rapid turnaround time, improving diagnostic efficiency in clinical and point-of-care settings. Its broad coverage and precise performance significantly aid timely clinical decision-making, particularly for managing respiratory infections with overlapping symptoms.
In February 2024, AstraZeneca plc, a pharmaceutical company based in the UK, acquired Icosavax Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to enhance its late-stage pipeline and expand its expertise in vaccines for respiratory conditions with high burdens, specifically advancing Icosavax’s lead investigational combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax Inc., a biotechnology company based in the US, focuses on developing vaccines, especially combination vaccines targeting respiratory viruses such as RSV and hMPV.
Major players in the human metapneumovirus diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Quest Diagnostics, Hologic Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, Qiagen NV, Diasorin, Luminex Corporation, bioMérieux, Seegene Inc., Cepheid, R-Biopharm AG, Certest Biotec, ZeptoMetrix, Xi'an Tianlong Science and Technology Co. Ltd, The Native Antigen Company, Hangzhou Testsea Biotechnology Co. Ltd., and Attogene.
North America was the largest region in the human metapneumovirus diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the human metapneumovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Human metapneumovirus (hMPV) diagnostics involve the methods and criteria used to detect and confirm infection with human metapneumovirus, a respiratory pathogen that can cause illnesses ranging from mild cold-like symptoms to severe respiratory infections, particularly in children, the elderly, and immunocompromised individuals.
The primary product types in human metapneumovirus diagnostics are reagents and kits, as well as instruments. Reagents and kits are essential laboratory products that contain chemical substances and tools for performing specific diagnostic tests or experiments. The diagnostic test types include molecular diagnostics, immunodiagnostics, culture-based methods, and others, utilizing technologies such as PCR-based diagnostics, next-generation sequencing (NGS), immunofluorescence assays, lateral flow assays, microarray technology, and others. These tests are used in various settings, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, among others.
The human metapneumovirus diagnostics market research report is one of a series of new reports that provides human metapneumovirus diagnostics market statistics, including human metapneumovirus diagnostics industry global market size, regional shares, competitors with a human metapneumovirus diagnostics market share, detailed human metapneumovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus diagnostics industry. This human metapneumovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human metapneumovirus diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, clinical laboratory services, point-of-care testing services, home sample collection services, public health surveillance services, and contract research and testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus diagnostics market also includes sales of sample collection devices, diagnostic data management tools, test validation kits, and safety and waste disposal systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The human metapneumovirus diagnostics market size is expected to see rapid growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth anticipated in the forecast period is driven by rising demand for early and accurate respiratory infection diagnostics, growing investments in point-of-care diagnostic solutions, expanding healthcare access in emerging markets, a global focus on pandemic preparedness, and greater integration of multiplex respiratory panels. Key trends in the forecast period include the development of automated and high-throughput diagnostic systems, a shift toward decentralized diagnostic models, the use of artificial intelligence in diagnostic interpretation, the increasing adoption of at-home testing kits, and growing collaboration between public and private diagnostic companies.
The increasing prevalence of respiratory infections is expected to drive growth in the human metapneumovirus diagnostics market. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the respiratory system, including the sinuses, throat, airways, and lungs. The rising prevalence can be linked to the exposure to harmful pollutants that irritate and weaken the respiratory tract, making it more susceptible to infections. Human metapneumovirus diagnostics help identify hMPV as the cause of respiratory infections, allowing for accurate treatment and better management. For example, in January 2025, the UK Health Security Agency reported that during the 2023-2024 season, respiratory infection rates in England peaked at 8 per 100,000 in weeks 50 and 52 of 2023, and rose further to 10.2 per 100,000 in week 4 of 2024, while acute respiratory infection incidents in closed settings reached 2,051, with most cases reported in care homes and hospitals. This growing prevalence of respiratory infections is fueling the expansion of the human metapneumovirus diagnostics market.
Leading companies in the human metapneumovirus diagnostics market are focusing on developing innovative solutions, such as respiratory polymerase chain reaction (PCR) diagnostic tools, to enhance molecular diagnostic capabilities for detecting a wide range of respiratory pathogens. A respiratory PCR diagnostic solution is a molecular testing method used to detect and identify respiratory pathogens by amplifying their genetic material with high sensitivity and specificity. For example, in March 2023, Jiangsu BioPerfectus Technologies Co., Ltd., a molecular diagnostic company based in China, launched its respiratory pathogen multiplex real-time PCR diagnostic kit. This solution is designed to simultaneously detect multiple respiratory pathogens with high accuracy and a rapid turnaround time, improving diagnostic efficiency in clinical and point-of-care settings. Its broad coverage and precise performance significantly aid timely clinical decision-making, particularly for managing respiratory infections with overlapping symptoms.
In February 2024, AstraZeneca plc, a pharmaceutical company based in the UK, acquired Icosavax Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to enhance its late-stage pipeline and expand its expertise in vaccines for respiratory conditions with high burdens, specifically advancing Icosavax’s lead investigational combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax Inc., a biotechnology company based in the US, focuses on developing vaccines, especially combination vaccines targeting respiratory viruses such as RSV and hMPV.
Major players in the human metapneumovirus diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Quest Diagnostics, Hologic Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, Qiagen NV, Diasorin, Luminex Corporation, bioMérieux, Seegene Inc., Cepheid, R-Biopharm AG, Certest Biotec, ZeptoMetrix, Xi'an Tianlong Science and Technology Co. Ltd, The Native Antigen Company, Hangzhou Testsea Biotechnology Co. Ltd., and Attogene.
North America was the largest region in the human metapneumovirus diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the human metapneumovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Human metapneumovirus (hMPV) diagnostics involve the methods and criteria used to detect and confirm infection with human metapneumovirus, a respiratory pathogen that can cause illnesses ranging from mild cold-like symptoms to severe respiratory infections, particularly in children, the elderly, and immunocompromised individuals.
The primary product types in human metapneumovirus diagnostics are reagents and kits, as well as instruments. Reagents and kits are essential laboratory products that contain chemical substances and tools for performing specific diagnostic tests or experiments. The diagnostic test types include molecular diagnostics, immunodiagnostics, culture-based methods, and others, utilizing technologies such as PCR-based diagnostics, next-generation sequencing (NGS), immunofluorescence assays, lateral flow assays, microarray technology, and others. These tests are used in various settings, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, among others.
The human metapneumovirus diagnostics market research report is one of a series of new reports that provides human metapneumovirus diagnostics market statistics, including human metapneumovirus diagnostics industry global market size, regional shares, competitors with a human metapneumovirus diagnostics market share, detailed human metapneumovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus diagnostics industry. This human metapneumovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human metapneumovirus diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, clinical laboratory services, point-of-care testing services, home sample collection services, public health surveillance services, and contract research and testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus diagnostics market also includes sales of sample collection devices, diagnostic data management tools, test validation kits, and safety and waste disposal systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Human Metapneumovirus Diagnostics Market Characteristics3. Human Metapneumovirus Diagnostics Market Trends And Strategies4. Human Metapneumovirus Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Human Metapneumovirus Diagnostics Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Human Metapneumovirus Diagnostics Market34. Recent Developments In The Human Metapneumovirus Diagnostics Market
5. Global Human Metapneumovirus Diagnostics Growth Analysis And Strategic Analysis Framework
6. Human Metapneumovirus Diagnostics Market Segmentation
7. Human Metapneumovirus Diagnostics Market Regional And Country Analysis
8. Asia-Pacific Human Metapneumovirus Diagnostics Market
9. China Human Metapneumovirus Diagnostics Market
10. India Human Metapneumovirus Diagnostics Market
11. Japan Human Metapneumovirus Diagnostics Market
12. Australia Human Metapneumovirus Diagnostics Market
13. Indonesia Human Metapneumovirus Diagnostics Market
14. South Korea Human Metapneumovirus Diagnostics Market
15. Western Europe Human Metapneumovirus Diagnostics Market
16. UK Human Metapneumovirus Diagnostics Market
17. Germany Human Metapneumovirus Diagnostics Market
18. France Human Metapneumovirus Diagnostics Market
19. Italy Human Metapneumovirus Diagnostics Market
20. Spain Human Metapneumovirus Diagnostics Market
21. Eastern Europe Human Metapneumovirus Diagnostics Market
22. Russia Human Metapneumovirus Diagnostics Market
23. North America Human Metapneumovirus Diagnostics Market
24. USA Human Metapneumovirus Diagnostics Market
25. Canada Human Metapneumovirus Diagnostics Market
26. South America Human Metapneumovirus Diagnostics Market
27. Brazil Human Metapneumovirus Diagnostics Market
28. Middle East Human Metapneumovirus Diagnostics Market
29. Africa Human Metapneumovirus Diagnostics Market
30. Human Metapneumovirus Diagnostics Market Competitive Landscape And Company Profiles
31. Human Metapneumovirus Diagnostics Market Other Major And Innovative Companies
35. Human Metapneumovirus Diagnostics Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Human Metapneumovirus Diagnostics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on human metapneumovirus diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for human metapneumovirus diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human metapneumovirus diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product Type: Reagents And Kits; Instruments2) By Test Type: Molecular Diagnostics; Immunodiagnostics; Culture Based Methods; Other Test Types
3) By Technology: PCR-Based Diagnostics; Next-Generation Sequencing (NGS); Immunofluorescence Assays; Lateral Flow Assays; Microarray Technology; Other Advanced Technologies
4) By End-Use: Hospitals And Clinics; Diagnostic And Reference Laboratories; Academic And Research Institutions; Other End Users
Subsegments:
1) By Reagents And Kits: Sample Collection Kits; Nucleic Acid Extraction Kits; Viral Transport Media; Control Reagents2) By Instruments: Thermal Cyclers; Automated Analyzers; Nucleic Acid Extractors; Fluorescence Readers
Key Companies Profiled: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Quest Diagnostics; Hologic Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Quest Diagnostics
- Hologic Inc.
- QuidelOrtho Corporation
- Bio-Rad Laboratories Inc.
- ARUP Laboratories
- Qiagen NV
- Diasorin
- Luminex Corporation
- bioMérieux
- Seegene Inc.
- Cepheid
- R-Biopharm AG
- Certest Biotec
- ZeptoMetrix
- Xi'an Tianlong Science and Technology Co. Ltd
- The Native Antigen Company
- Hangzhou Testsea Biotechnology Co. Ltd.
- Attogene.